No, I don’t think so. Think about when the last treatment censor patient entered into the red line of the combo trial. It had already been ** 170 days, with no new censored patients behind him apparently. The regulators can look at parallel similar trials to make determinations on either the active trial or the ending MAA. That data is now another 240 days matured.
** In other words, I don’t think they plan on adding anymore patients. Perhaps they are thinking about a halt for efficacy, as CaptainO opined.